Caley Smith, Ph.D.
About Caley Smith, Ph.D.
Caley Smith, Ph.D., is a Study Director I in Pharmacology with expertise in viral mediated gene therapy and in vivo preclinical animal studies. He has contributed to the development of novel mouse models for spinal muscular atrophy and has experience in managing relationships with Contract Research Organizations.
Current Role at Inotiv
Caley Smith, Ph.D., serves as Study Director I in Pharmacology at Inotiv, a position held since 2022. In this role, Smith oversees pharmacological studies, ensuring adherence to regulatory standards and timelines. Smith's responsibilities include designing and implementing preclinical studies, as well as collaborating with various teams to advance research objectives. The role emphasizes the importance of effective communication and project management within the pharmacology domain.
Education and Expertise
Caley Smith earned a Doctor of Philosophy (Ph.D.) in Gene/Genetic Therapy from the University of Missouri-Columbia, where studies were conducted from 2017 to 2021. Prior to this, Smith obtained a Bachelor of Science (BS) in Biology from Truman State University, completing the degree from 2013 to 2017. Smith's academic background is complemented by expertise in viral mediated gene therapy and in vivo preclinical animal studies, which are critical in the field of pharmacology.
Professional Background
Smith's professional journey includes significant roles in research and academia. Prior to joining Inotiv, Smith worked as a Research Scientist I at M6P Therapeutics from 2021 to 2022, where responsibilities included managing timelines for preclinical testing and developing relationships with Contract Research Organizations (CROs). Smith also served as an Undergraduate Research Student at A.T. Still University from 2015 to 2017, focusing on novel mouse models for spinal muscular atrophy.
Research Contributions and Projects
During the tenure at A.T. Still University, Caley Smith characterized novel mouse models for spinal muscular atrophy with respiratory distress type I (SMARD1). This work marked a significant advancement as it was the first instance of a mouse model with quantifiable respiratory deficiencies. Smith has also presented research findings at national conferences, contributing to the broader scientific community and sharing insights on gene therapy and pharmacology.
Collaborative Efforts
Caley Smith has a history of collaboration with team members on various research projects. This collaborative approach is essential in the field of pharmacology, where interdisciplinary teamwork can enhance research outcomes. Smith's ability to work effectively within a team setting supports the successful execution of complex studies and the advancement of pharmacological research initiatives.